Sweet Earth Holdings Past Earnings Performance
Past criteria checks 2/6
Sweet Earth Holdings has been growing earnings at an average annual rate of 35.5%, while the Pharmaceuticals industry saw earnings growing at 12.9% annually. Revenues have been growing at an average rate of 12.7% per year.
Key information
35.5%
Earnings growth rate
51.9%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 12.7% |
| Return on equity | n/a |
| Net Margin | 1,891.4% |
| Last Earnings Update | 30 Jun 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Sweet Earth Holdings makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 0 | 0 | 0 | 0 |
| 31 Mar 24 | 0 | 0 | 0 | 0 |
| 31 Dec 23 | 0 | 0 | 0 | 0 |
| 30 Sep 23 | 0 | 0 | 0 | 0 |
| 30 Jun 23 | 0 | 0 | 0 | 0 |
| 31 Mar 23 | 0 | -2 | 1 | 0 |
| 31 Dec 22 | 0 | -2 | 1 | 0 |
| 30 Sep 22 | 0 | -3 | 1 | 0 |
| 30 Jun 22 | 0 | -3 | 1 | 0 |
| 31 Mar 22 | 0 | -3 | 1 | 0 |
| 31 Dec 21 | 0 | -4 | 3 | 0 |
| 30 Sep 21 | 0 | -5 | 4 | 0 |
| 30 Jun 21 | 0 | -5 | 4 | 0 |
| 31 Mar 21 | 0 | -6 | 4 | 0 |
| 31 Dec 20 | 0 | -5 | 4 | 0 |
| 30 Sep 20 | 0 | -5 | 4 | 0 |
| 30 Jun 20 | 0 | -5 | 4 | 0 |
| 31 Mar 20 | 0 | -5 | 6 | 0 |
| 31 Dec 19 | 0 | -5 | 5 | 0 |
| 30 Sep 19 | 0 | -4 | 4 | 0 |
Quality Earnings: 1KZ0 has a large one-off gain of CA$629.5K impacting its last 12 months of financial results to 30th June, 2024.
Growing Profit Margin: 1KZ0 became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 1KZ0 has become profitable over the past 5 years, growing earnings by 35.5% per year.
Accelerating Growth: 1KZ0 has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: 1KZ0 has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (28.7%).
Return on Equity
High ROE: 1KZ0's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.